glimepiride + vildagliptin + metformin

Glimepiride + vildagliptin + metformin is a fixed-dose combination oral medication used for the management of type 2 diabetes mellitus. Each component has a distinct mechanism of action that targets different aspects of glucose regulation: - Glimepiride is a sulfonylurea that stimulates insulin secretion from pancreatic beta-cells. - Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which increases incretin levels, thereby enhancing insulin secretion and suppressing glucagon release in response to meals. - Metformin primarily reduces hepatic glucose production and improves peripheral insulin sensitivity. This triple therapy aims to provide improved glycemic control in adults with type 2 diabetes who are inadequately controlled on dual therapy or monotherapy. The combination leverages complementary mechanisms to maximize efficacy while minimizing side effects such as hypoglycemia and weight gain[1][3][8].

Other names

glimepiride/vildagliptin/metformin hydrochloride